Current assets: |
Cash and cash equivalents |
127.94M |
Restricted cash |
Short-term investments |
Trade accounts receivable, net |
48.58M |
Prepaid expenses |
15.64M |
Finished goods inventory held by the Company |
Finished goods inventory held by others |
Other current assets |
4.86M |
Total current assets |
237.95M |
Property and equipment, net of accumulated depreciation |
35.78M |
Intangible assets, net of accumulated amortization |
749.42M |
Non-current portion of deferred cost of license revenue |
2.43M |
Other assets |
5.81M |
Total assets |
1.32B |
Current liabilities: |
Accounts payable |
18.56M |
Accrued expenses and other current liabilities |
89.37M |
Deferred product revenue-Zanaflex tablets |
Deferred product revenue-Zanaflex Capsules |
Current portion of deferred license revenue |
9.06M |
Current portion of revenue interest liability |
Current portion of convertible notes payable |
1.13M |
Total current liabilities |
118.12M |
Non-current portion of deferred license revenue |
34.72M |
Put/call liability |
Non-current portion of revenue interest liability |
Non-current portion of convertible notes payable |
0 |
Stockholders' equity: |
Common stock, $0.001 par value. Authorized 80,000,000 shares at June 30, 2011 and December 31, 2010; issued and outstanding 39,106,856 and 38,779,370 shares as of June 30, 2011 and December 31, 2010, respectively |
46K |
Treasury stock at cost (12,420 shares at June 30, 2011 and December 31, 2010) |
-329K |
Additional paid-in capital |
911.54M |
Accumulated deficit |
-240.88M |
Accumulated other comprehensive income |
-3.62M |
Total stockholders' equity |
666.77M |
Total liabilities and stockholders' equity |
1.32B |